As long as the experimental design is structured so that the end samples can be incorporated into the assay as suggested and there is enough cAMP/cGMP present for the kit to detect, these kits should be efficient in detecting fluctuations caused by various agonists or antagonists. It is, of course, up to the end user to establish a detectable baseline level of cAMP/cGMP in the samples and then optimize treatments with the agonist or antagonist of choice.

Leave a comment